DrugPatentWatch Database Preview

Teva Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has six hundred and ninety-eight approved drugs.

There are seventy-one US patents protecting TEVA drugs. There are forty-seven tentative approvals on TEVA drugs.

There are eight hundred and four patent family members on TEVA drugs in forty-six countries and seven hundred and twenty-five supplementary protection certificates in eighteen countries.

Summary for Teva

International Patents:	804
US Patents:	71
Tradenames:	473
Ingredients:	412
NDAs:	698
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017		RX	Yes	No	8,006,690		Y
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007	AB	RX	Yes	Yes	7,790,199		Y
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-006	Jul 12, 2019		RX	Yes	No	8,978,966		Y

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,939,539
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-001	Mar 26, 1993	4,258,062*PED
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	5,981,589

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.5 mg and 1 mg		2010-05-17
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Drugs

Country	Patent Number	Estimated Expiration
Japan	2016154899
Japan	5806354
Austria	281861

Supplementary Protection Certificates for Teva Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
0900210	C00900210/01	Switzerland		PRODUCT NAME: ATAZANAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56288 06.05.2004
0497512	99C0011	Belgium		PRODUCT NAME: RIZATRIPTAN BENZOAS EQ. RIZATRIPTAN; REGISTRATION NO/DATE: 922 IS 181 F 3 19981130; FIRST REGISTRATION: NL RVG 21815 19980211

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral